DiSilvestro P A, Gajewski W H, Ludwig M E, Kourea H, Sung J, Granai C O
Women & Infants Hospital/Brown University, Providence, Rhode Island, USA.
Obstet Gynecol. 1995 Nov;86(5):780-2. doi: 10.1016/0029-7844(95)00285-Y.
To review the experience at Women & Infants Hospital and Hartford Hospital of patients with malignant mixed mesodermal tumors of the ovary, and to review the pertinent literature.
Fourteen cases of malignant mixed mesodermal tumors of the ovary at the two hospitals over a 5-year period were identified through their tumor registries. Demographic data, pathology, treatment, and survival rates were reviewed.
The median survival of the patients in our series was 7 months, with 64% dead of disease in 1 year. A review of the pertinent literature indicated median survivals of 6-12 months, with more than 70% of the patients dead of disease at 1 year, despite treatment.
Further investigation is needed to determine the proper management for malignant mixed mesodermal tumors of the ovary. Meanwhile, current treatment strategies should recognize the present therapeutic limitations, so as not to diminish any further the quality of life for women with this malignancy.
回顾妇女与婴儿医院及哈特福德医院卵巢恶性中胚叶混合瘤患者的治疗经验，并复习相关文献。
通过肿瘤登记处识别出两家医院在5年期间的14例卵巢恶性中胚叶混合瘤病例。回顾了人口统计学数据、病理学、治疗方法及生存率。
我们系列研究中患者的中位生存期为7个月，1年内64%死于疾病。相关文献回顾表明，尽管接受了治疗，但中位生存期为6至12个月，1年内超过70%的患者死于疾病。
需要进一步研究以确定卵巢恶性中胚叶混合瘤的恰当治疗方法。同时，当前的治疗策略应认识到目前的治疗局限性，以免进一步降低患有这种恶性肿瘤的女性的生活质量。
